Literature DB >> 20096816

[Surgical treatment of head and neck chondrosarcomas].

Sergio Obeso1, José Luis Llorente, Juan Pablo Díaz-Molina, Rafael Sánchez-Fernández, Juan Pablo Rodrigo, Carlos Suárez.   

Abstract

INTRODUCTION: Head and neck chondrosarcomas may adopt different locations and biological behaviour. MATERIAL AND
METHOD: We present a retrospective clinical series of 17 chondrosarcomas surgically treated in our Department from 1977 until 2006.
RESULTS: Chondrosarcomas were located in the nasosinusal area (n=6), larynx (n=5), petrous bone (n=3), atlas (n=1), parapharyngeal space (n=1) and trachea (n=1). All patients except for one underwent surgery with radical intention. The mean follow-up period was 84 months (median, 71 months). Six patients developed recurrent disease with a mean latency of 10 months. Two patients died due to the disease and two remained alive with evidence of tumour. Patients with grade I chondrosarcomas presented less recurrent disease than those with grade II or III chondrosarcomas (17% versus 80%, P=0.029). The estimated 5-year survival was 88% with the better survival of patients with grade I chondrosarcomas reaching statistical significance (P=0.023). In 2 patients with cricoid chondrosarcomas, the reconstruction was carried out using the Rethi-Ward technique, and they were without evidence of disease at 71 months (with no cannula) and 145 months (with cannula). Chondrosarcomas of the jugular foramen were treated using a modified infratemporal type A approach.
CONCLUSION: Low grade head and neck chondrosarcomas have a good prognosis while high grade chondrosarcomas tend to recur, despite radical surgical treatment. Copyright 2009 Elsevier España, S.L. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20096816     DOI: 10.1016/j.otorri.2009.12.002

Source DB:  PubMed          Journal:  Acta Otorrinolaringol Esp        ISSN: 0001-6519


  8 in total

1.  Chondrosarcoma of Nasal Cavity: a Rare Entity.

Authors:  Pankaj Kumar Sahu; Lovraj Goyal; Jitendra Bothra; Pragya Sharma
Journal:  Indian J Surg Oncol       Date:  2020-08-28

Review 2.  Chondrosarcomas of the head and neck.

Authors:  Andrés Coca-Pelaz; Juan P Rodrigo; Asterios Triantafyllou; Jennifer L Hunt; Juan C Fernández-Miranda; Primož Strojan; Remco de Bree; Alessandra Rinaldo; Robert P Takes; Alfio Ferlito
Journal:  Eur Arch Otorhinolaryngol       Date:  2013-11-10       Impact factor: 2.503

3.  Orbital chondrosarcoma arising from paranasal sinuses.

Authors:  Hayyam Kiratli; Ozlem Dikmetaş; Berçin Tarlan; Metin Onerci
Journal:  Int Ophthalmol       Date:  2012-11-06       Impact factor: 2.031

4.  Well and intermediate differentiated laryngeal chondrosarcoma: toward conservative surgery?

Authors:  Valerio Damiani; Erika Crosetti; Giuseppe Rizzotto; Angelo Camaioni; Giovanni Succo
Journal:  Eur Arch Otorhinolaryngol       Date:  2013-08-23       Impact factor: 2.503

5.  Tracheal Chondrosarcoma: Systematic Review of Tumor Characteristics, Diagnosis, and Treatment Outcomes with Case Report.

Authors:  Emily A Kutzner; Joshua S Park; Salman Zaheer; Jared C Inman
Journal:  Case Rep Oncol Med       Date:  2017-05-23

6.  Nasal Chondrosarcoma of the Lower Lateral Cartilage.

Authors:  Hannah B Tan; Joanne Rimmer
Journal:  Medicina (Kaunas)       Date:  2019-05-09       Impact factor: 2.430

7.  Chondrosarcoma of the parapharyngeal space: Case report and literature review of an extremely rare location.

Authors:  Meryeme Chihabeddine; Asmaa Naim; Mariam Kassimi; Jihane Habi; Mohamed Mahi; Meriem Damou; Nabil Ismaili; Wafaa Kaikani; Fadila Kouhen
Journal:  Radiol Case Rep       Date:  2021-02-26

8.  Conventional grade 1 chondrosarcoma: a challenging diagnosis with important implications on therapy and prognosis.

Authors:  Gabriel Veniamin Cozma; Laurenţiu Vasile Sima; Raluca Maria Cloşca; Flavia Baderca; Ioana Delia Horhat; Nicolae Constantin Balica; Alina Andreea Tischer; Ion Cristian Moţ; Daniel Claudiu Maliţa; Aurel Marin; Cristian Andrei Sarău
Journal:  Rom J Morphol Embryol       Date:  2021 Apr-Jun       Impact factor: 1.033

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.